Sec Form 4 Filing - Nelli James Patrick Jr. @ Health Catalyst, Inc. - 2020-06-19

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Nelli James Patrick Jr.
2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Financial Officer
(Last) (First) (Middle)
C/O HEALTH CATALYST, INC., 3165 MILLROCK DRIVE, #400
3. Date of Earliest Transaction (MM/DD/YY)
06/19/2020
(Street)
SALT LAKE CITY, UT84121
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/19/2020 M 15,497 A $ 10.72 122,845 D
Common Stock 06/19/2020 M 14,360 A $ 10.8 137,205 D
Common Stock 06/19/2020 M 417 A $ 10.66 137,622 D
Common Stock 06/19/2020 S( 1 ) 15,497 D $ 32.09 ( 2 ) 107,348 D
Common Stock 06/19/2020 S( 1 ) 14,360 D $ 32.08 ( 3 ) 123,262 D
Common Stock 06/19/2020 S( 1 ) 417 D $ 32 122,845 D
Common Stock 06/19/2020 S( 1 ) 6,500 D $ 32 100,848 D
Common Stock 06/22/2020 M 11,139 A $ 10.8 144,074 D
Common Stock 06/22/2020 M 32,087 A $ 10.72 132,935 D
Common Stock 06/22/2020 S( 1 ) 11,139 D $ 32.3 ( 4 ) 132,935 D
Common Stock 06/22/2020 S( 1 ) 31,308 D $ 32.68 ( 5 ) 101,627 D
Common Stock 06/22/2020 S( 1 ) 779 D $ 33 ( 6 ) 100,848 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 10.72 06/19/2020 M 15,497 ( 7 ) 10/26/2027 Common Stock 15,497 $ 0 76,249 D
Stock Option (Right to Buy) $ 10.8 06/19/2020 M 14,360 ( 8 ) 09/27/2028 Common Stock 14,360 $ 0 210,640 D
Stock Option (Right to Buy) $ 10.66 06/19/2020 M 417 ( 9 ) 04/27/2027 Common Stock 417 $ 0 15,087 D
Stock Option (Right to Buy) $ 10.8 06/22/2020 M 11,139 ( 8 ) 09/27/2028 Common Stock 11,139 $ 0 199,501 D
Stock Option (Right to Buy) $ 10.72 06/22/2020 M 32,087 ( 7 ) 10/26/2027 Common Stock 32,087 $ 0 44,162 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Nelli James Patrick Jr.
C/O HEALTH CATALYST, INC.
3165 MILLROCK DRIVE, #400
SALT LAKE CITY, UT84121
Chief Financial Officer
Signatures
/s/ Daniel Orenstein, as Attorney-in-Fact 06/23/2020
Signature of Reporting Person Date
Explanation of Responses:
( 1 )The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on November 22, 2019, in accordance with Rule 10b5-1.
( 2 )Represents the weighted average sale price of the shares sold ranging from $32.00 to $32.32 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
( 3 )Represents the weighted average sale price of the shares sold ranging from $32.00 to $32.31 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
( 4 )Represents the weighted average sale price of the shares sold ranging from $32.00 to $32.85 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
( 5 )Represents the weighted average sale price of the shares sold ranging from $32.00 to $32.99 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
( 6 )Represents the weighted average sale price of the shares sold ranging from $33.00 to $33.01 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
( 7 )25% of the shares vested on October 26, 2018 and the remaining 75% vest in 36 equal monthly installments thereafter.
( 8 )25% of the shares vested on September 25, 2019 and the remaining 75% vest in 36 equal monthly installments thereafter.
( 9 )25% of the shares vested on April 27, 2018 and the remaining 75% vest in 36 equal monthly installments thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.